Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company
committed to discovering and delivering the next generation of
precision cancer medicines, today announced that three abstracts
have been selected for poster presentation at the Society for
Immunotherapy of Cancer (SITC) 37th Annual Meeting, November 8-12,
2022, in Boston, Massachusetts, and online.
“We are looking forward to presenting data on TNG260, a novel,
highly selective CoREST inhibitor with the potential to reverse the
immune evasion driven by STK11 loss-of-function mutations. STK11
mutations occur in approximately 15% of non-small cell lung cancers
and render those tumors resistant to checkpoint inhibitors,” said
Barbara Weber, M.D., President, and Chief Executive Officer of
Tango Therapeutics. “This program is among the first to bring the
power of genetic patient selection to immuno-oncology development,
and we plan to submit an IND in the first half of next year. We
also will be presenting data on our novel in vivo and in vitro
functional genomic platforms, designed to identify additional
immune evasion targets linked to specific tumor suppressor gene
loss.”
Details on the Tango presentations at the SITC
37th Annual Meeting are as
follows:
Poster Title: TNG260, a CoREST-selective
deacetylase inhibitor, reverses anti-PD1 resistance driven by loss
of STK11Abstract #: 444Date and
Time: Thursday, November 11, 2022, 9:00 AM ET
Poster Title: In vivo CRISPR screens
identify HDAC1 as an immune sensitizer reversing immune resistance
driven by STK11 lossAbstract
#: 1425Date and
Time: Wednesday, November 10, 2022, 9:00 AM ET
Poster Title: Whole genome CRISPR-Cas9
screens in a cancer cell line panel co-cultured with
antigen-specific cytotoxic CD8 T cells are a powerful engine for
immuno-oncology drug target discoveryAbstract #:
70Date and Time: Thursday, November 11, 2022,
9:00 AM ET
Poster Title: Leveraging CRISPR-Cas9
screening platform for discovery of novel tumor intrinsic
phagocytosis modulatorsAbstract
#: 1449Date and
Time: Wednesday, November 10, 2022, 9:00 AM ET
About TNG260, a novel CoREST inhibitor
STK11 loss-of-function mutations occur in ~15% of non-small cell
lung cancer and drive immune evasion, rendering STK11-mutant tumors
insensitive to the immune checkpoint inhibitor therapy that
significantly prolongs survival in STK11-wild type cancers. STK11
mutations also are found in ~15% of cervical cancer, 10% of
carcinoma of unknown primary, 5% of breast cancer and 3% of
pancreatic cancer. TNG260 is a novel small molecule inhibitor of
the Co-repressor of Repressor Element-1 Silencing Transcription
(CoREST) deacetylase complex. TNG260 is being developed to reverse
immune evasion in STK11 mutated cancers, with the aim of restoring
sensitivity to immune checkpoint inhibition. In preclinical
studies, selective CoREST inhibition by TNG260 results in
transcriptional reprogramming of STK11-mutant tumor cells, altering
tumor cell cytokine secretion and markedly reducing recruitment of
suppressive T cells to STK11-mutant tumors. TNG260 in combination
with anti-PD1 treatment drives complete regressions in multiple
syngeneic STK11-mutant xenograft models. The Company expects to
file an Investigational New Drug (IND) application for TNG260 in
the first half of 2023.
About Tango Therapeutics
Tango Therapeutics is a biotechnology company dedicated to
discovering novel drug targets and delivering the next generation
of precision medicine for the treatment of cancer. Using an
approach that starts and ends with patients, Tango leverages the
genetic principle of synthetic lethality to discover and develop
therapies that take aim at critical targets in cancer. This
includes expanding the universe of precision oncology targets into
novel areas such as tumor suppressor gene loss and their
contribution to the ability of cancer cells to evade immune cell
killing. For more information, please visit www.tangotx.com.
Forward-Looking Statements
Certain statements in this press release may be considered
forward-looking statements. Forward-looking statements generally
relate to future events, Tango’s future operating performance and
goals, the anticipated benefits of therapies and combination
therapies (that include a Tango pipeline product), expectations,
beliefs and development objectives for Tango’s product pipeline and
clinical trials. In some cases, you can identify forward-looking
statements by terminology such as “may”, “should”, “expect”,
“intend”, “will”, “goal”, “estimate”, “anticipate”, “believe”,
“predict”, “potential” or “continue”, or the negatives of these
terms or variations of them or similar terminology. For example,
statements concerning the following include or constitute
forward-looking statements: TNG260 has the potential to reverse the
immune evasion driven by STK11 mutations; the Company expects to
file an Investigational New Drug (IND) application for TNG260 in
the first half of 2023; Tango’s functional genomic platforms are
designed to identify additional immune evasion targets linked to
specific tumor suppressor gene loss; and the expected timing of:
(i) development candidate declaration for certain targets; (ii)
initiating IND-enabling studies; (iii) filing INDs; (iv) clinical
trial initiation; and (v) disclosing initial and final clinical
trial results. Such forward-looking statements are subject to
risks, uncertainties, and other factors which could cause actual
results to differ materially from those expressed or implied by
such forward looking statements. These forward-looking statements
are based upon estimates and assumptions that, while considered
reasonable by Tango and its management, are inherently uncertain.
New risks and uncertainties may emerge from time to time, and it is
not possible to predict all risks and uncertainties. Factors that
may cause actual results to differ materially from current
expectations include, but are not limited to: the expected benefits
of Tango pipeline products, development candidates and potential
combination therapies that are seen in pre-clinical experiments may
not be present in clinical trials or when used commercially or may
not be safe and/or effective in humans; Tango’s functional genomic
platforms may not identify immune evasion targets as expected, or
at all; TNG260 may not reverse the immune evasion driven by STK11
mutations; Tango has limited experience conducting clinical trials
and may not be able to commence the clinical trial when expected
and may not generate results in the anticipated timeframe (or at
all); the expected benefits of product candidates may not be
evident when tested in the pre-clinical setting, clinical trials or
when used in broader patient populations (if approved for
commercial sale); Tango has a limited operating history and has not
generated any revenue to date from drug sales, and may never become
profitable; the Company may not be able to identify development
candidates on the schedule it anticipates due to technical,
financial or other reasons; the Company may not be able to file
INDs for development candidates on time, or at all, due to
technical or financial reasons or otherwise; the Company may
utilize cash resources more quickly than anticipated; Tango will
need to raise capital in the future and if we are unable to raise
capital when needed or on attractive terms, we would be forced to
delay, scale back or discontinue some of our development programs,
regulatory filings, or future commercialization efforts; we may be
unable to advance our preclinical development programs into and
through the clinic for safety or efficacy reasons or commercialize
our product candidates or we may experience significant delays in
doing so as a result of factors beyond Tango’s control; Tango’s
approach to the discovery and development of product candidates is
novel and unproven (including its discovery platform), which makes
it difficult to predict the time, cost of development, and
likelihood of successfully developing any products; Tango may not
identify or discover additional product candidates or may expend
limited resources to pursue a particular product candidate or
indication and fail to capitalize on product candidates or
indications that may be more profitable or for which there is a
greater likelihood of success; our products candidates may cause
adverse or other undesirable side effects (or may not show
requisite efficacy) that could, among other things, delay or
prevent regulatory approval; our dependence on third parties for
conducting clinical trials and producing drug product; our ability
to obtain and maintain patent and other intellectual property
protection for our technology and product candidates or the scope
of intellectual property protection obtained is not sufficiently
broad; and delays and other impacts on product development and
clinical trials from the COVID-19 pandemic. Additional information
concerning risks, uncertainties and assumptions can be found in
Tango’s filings with the SEC, including the risk factors referenced
in Tango’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2021, as supplemented and/or modified by its most
recent Quarterly Report on Form 10-Q. You should not place undue
reliance on forward-looking statements in this presentation, which
speak only as of the date they are made and are qualified in their
entirety by reference to the cautionary statements herein. Tango
specifically disclaims any duty to update these forward-looking
statements.
Investor Contact:
Sam Martin/Andrew VulisArgot Partnerstango@argotpartners.com
Media Contact:
Joshua R. Mansbach Argot Partners tango@argotpartners.com
Tango Therapeutics (NASDAQ:TNGX)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Tango Therapeutics (NASDAQ:TNGX)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024